Spatial Model for Oncolytic Virotherapy with Lytic Cycle Delay

Springer Science and Business Media LLC - Tập 81 - Trang 2396-2427 - 2019
Jiantao Zhao1,2, Jianjun Paul Tian1,3
1Department of Mathematical Sciences, New Mexico State University, Las Cruces, USA
2School of Mathematical Sciences, Heilongjiang University, Harbin, People’s Republic of China
3School of Mathematics and Computer Science, Shaanxi University of Technology, Hanzhong, People’s Republic of China

Tóm tắt

We formulate a mathematical model of functional partial differential equations for oncolytic virotherapy which incorporates virus diffusivity, tumor cell diffusion, and the viral lytic cycle based on a basic oncolytic virus dynamics model. We conduct a detailed analysis for the dynamics of the model and carry out numerical simulations to demonstrate our analytic results. Particularly, we establish the positive invariant domain for the $$\omega $$ limit set of the system and show that the model has three spatially homogenous equilibriums solutions. We prove that the spatially uniform virus-free steady state is globally asymptotically stable for any viral lytic period delay and diffusion coefficients of tumor cells and viruses when the viral burst size is smaller than a critical value. We obtain the conditions, for example the ratio of virus diffusion coefficient to that of tumor cells is greater than a value and the viral lytic cycle, is greater than a critical value, under which the spatially uniform positive steady state is locally asymptotically stable. We also obtain conditions under which the system undergoes Hopf bifurcations, and stable periodic solutions occur. We point out medical implications of our results which are difficult to obtain from models without combining diffusive properties of viruses and tumor cells with viral lytic cycles.

Tài liệu tham khảo

Bajzer Ž, Carr T, Josić K et al (2008) Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol 252(1):109–122 Barish S, Ochs MF, Sontag EO, Gevertz J (2017) Evaluation optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. In: PNAS E6277–E6286 Boeuf FL, Batenchuk C, Koskela MV, Breton S, Roy D, Lemay C et al (1974) Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 2013:4 Chiocca EA (2002) Oncolytic viruses. Nat Rev Cancer 2(12):938 Chiocca EA, Rabkin SD (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2(4):295–300 Choudhury B, Nasipuri B (2014) Efficient virotherapy of cancer in the presence of immune response. Int J Dyn Control 2:314–325 Faria T (2000) Normal forms and Hopf bifurcation for partial differential equations with delays. Trans Am Math Soc 352(5):2217–2238 Friedman A, Lai X (2018) Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: a mathematical model. PloS ONE 13(2):e0192449 Friedman A, Tian JP, Fulci G et al (2006) Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 66(4):2314–2319 Harpold HL, Alvord EC Jr, Swanson KR (2007) The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66(1):1–9 Hassard BD, Kazarinoff ND, Wan YH (1981) Theory and applications of Hopf bifurcation. Cambridge University Press, Cambridge Jenner AL, Coster ACF, Kim PS, Frascoli F (2018) Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy. Lett Biomath 5:S117–S136. https://doi.org/10.1080/23737867.2018.1440977 Kaplan JM (2005) Adenovirus-based cancer gene therapy. Curr Gene Ther 5(6):595–605 Karev GP, Novozhilov AS, Koonin EV (2006) Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics. Biol Direct 1(1):30 Kirn DH, McCormick F (1996) Replicating viruses as selective cancer therapeutics. Mol Med Today 2(12):519–527 Lawler SE, Speranza MC, Cho CF et al (2017) Oncolytic viruses in cancer treatment: a review. JAMA Oncol 3(6):841–849 Lin X, So JWH, Wu J (1992) Centre manifolds for partial differential equations with delays. Proc R Soc Edinb Sect A Math 122(3–4):237–254 Mahasa KJ, Eladdadi A, Pillis L d, Ouifki R (2017) Oncolytic potency and reduced vuris tumor-specificity in oncolytic virotherapy, a mathematical modeling approach. PloS ONE 12(9):e0184347 Maroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng KW, Russell S (2017) Designing and building oncolytic viruses. Future Virol 12(4):193–213 Martuza RL, Malick A, Markert JM et al (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252(5007):854–856 Massey SC, Rockne RC, Hawkins-Daarud A, Gallaher J, Anderson ARA, Canoll P, Swanson KR (2018) Simulating PDGF-driven glioma growth and invasion in an anatomically accurate brain domain. Bull Math Biol 80:1292–12309 Mok W, Stylianopoulos T, Boucher Y, Jain RK (2009) Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res 15(7):2352–2360 Novozhilov AS, Berezovskaya FS, Koonin EV et al (2006) Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models. Biol Direct 1(1):6 Phan TA, Tian JP (2017) The role of the innate immune system in oncolytic virotherapy. Comput Math Methods Med 6587258 Ratajczyk E, Ledzewicz U, Leszczynski M, Schattler H (2018) Treatment of glioma with virotherapy and TNF-a inhibitors: analysis as a dynamical system. Discrete Contin Dyn Syst B 23(1):425–441 Roberts MS, Lorence RM, Groene WS et al (2006) Naturally oncolytic viruses. Curr Opin Mol Ther 8(4):314–321 Swanson KR, Alvord EC, Murray JD (2002) Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 86:14–18 Tian JP (2011) The replicability of oncolytic virus: defining conditions in tumor virotherapy. Math Biosci Eng 8(3):841–860 Timalsina A, Tian JP, Wang J (2017) Mathematical and computational modeling for tumor virotherapy with mediated immunity. Bull Math Biol 79(8):1736–1758 Vasiliu D, Tian JP (2011) Periodic solutions of a model for tumor virotherapy. Discrete Contin Dyn Syst S 4(6):1587–1597 Wang Y, Tian JP, Wei J (2013) Lytic cycle: a defining process in oncolytic virotherapy. Appl Math Model 37(8):5962–5978 Wang Z, Guo Z, Peng H (2017) Dynamical behavior of a new oncolytic virotherapy model based on gene variation. Discrete Contin Dyn Syst S 10(5):1079–1093 Wares J, Crivelli J, Yun CO, Choi IK, Gevertz J, Kim P (2015) Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. Math Biosci Eng 2(6):1237–1256 Wein LM, Wu JT, Kirn DH (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63(6):1317–1324 Wodarz D (2001) Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 61(8):3501–3507 Wodarz D, Komarova N (2009) Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection. PloS ONE 4(1):e4271 Wodarz D, Hofacre A, Lau JW, Sun Z, Fan H, Komarova N (2012) Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PloS Comput Biol 8(6):e1002547 Wu J (2012) Theory and applications of partial functional differential equations. Springer, Berlin Wu JT, Byrne HM, Kirn DH et al (2001) Modeling and analysis of a virus that replicates selectively in tumor cells. Bull Math Biol 63(4):731